SCHEDULE 13G: Anson Funds Group Discloses 7% Passive Stake in NRX Pharmaceuticals

Anson Funds Management LP and its affiliates have disclosed a 7% passive beneficial ownership stake in NRX Pharmaceuticals, Inc., totaling 1,179,061 shares of common stock.

Summary

• Anson Funds Management LP, Anson Management GP LLC, Mr. Tony Moore, Anson Advisors Inc., Mr. Amin Nathoo, and Mr. Moez Kassam collectively reported beneficial ownership of 1,179,061 shares of NRX Pharmaceuticals, Inc. common stock.
• This represents 7% of the outstanding common stock of NRX Pharmaceuticals, Inc.
• The percentage is calculated based on 16,915,647 shares of common stock outstanding, as reported in NRX Pharmaceuticals' Annual Report on Form 10-K filed with the SEC on March 14, 2025.
• The filing is a Schedule 13G, indicating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a neutral, factual regulatory disclosure of beneficial ownership, providing no explicit positive or negative sentiment regarding the issuer's performance or prospects.

Positives

• The disclosure of a significant 7% stake by an institutional investor group like Anson Funds could be interpreted by some market participants as a signal of confidence in NRX Pharmaceuticals, although the filing itself is a purely factual regulatory disclosure and does not express an opinion on the company's prospects.

Negatives

• The document itself does not contain any negative information regarding NRX Pharmaceuticals; it is a factual disclosure of ownership.

Risks

• No specific business or operational risks for NRX Pharmaceuticals are mentioned in this beneficial ownership disclosure document.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding NRX Pharmaceuticals' future outlook.

Management Comments

• The document contains certifications from the reporting persons stating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Industry Context

This filing is a standard regulatory disclosure of a significant passive ownership stake by an investment group in a pharmaceutical company. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• Not applicable, as this document is a beneficial ownership disclosure and does not contain performance metrics or operational data for comparison against industry standards or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's passive stake in the company, which can influence investor perception and potentially liquidity.

Next Steps

• The reporting persons will be required to file amendments to this Schedule 13G if there are material changes to their beneficial ownership or if their investment intent changes from passive to active.

Key Dates

Keywords

NRX Pharmaceuticals, Anson Funds, Schedule 13G, beneficial ownership, common stock, institutional investor, SEC filing, passive investment